FDA quietly announced last week that it was resuming domestic surveillance inspections for drugs and other regulated products after another hiatus due to the pandemic. Regular FDA field inspections have been halted several times since March 2020, most recently at the end of 2021; the spread of the omicron variant boosted COVID-19 infections, raising fears that FDA inspectors as well as local plant personnel could be exposed to the virus from such interactions.